Issue 108 • July 2021

The hunt for shark squalene alternative

Reducing surgical scarring with drugs

Is a new malaria vaccine on the horizon?

Time for UK plasma to shine

After 20 years, the UK Government’s ban on the use of UK human blood plasma for the production of plasma-derived therapies has been lifted. So what happens now?

02/24/2024 07:38:56

06/18/2021 00:00:00

Go to article: Home | Time for UK plasma to shine Go to article: In this issue Go to article: Contents Go to article: Datwyler Go to article: Labcorp Go to article: UPS Healthcare Company Insight Go to article: UPS Healthcare Go to article: Baxter Go to article: SHL Medical Go to article: Briefing Go to article: Industry news Go to article: The pharma industry briefing Go to article: Covid-19 executive briefing by GlobalData Go to article: Mimotopes Company Insight Go to article: Mimotopes Go to article: PerkinElmer Go to article: Comment Go to article: A new day for Alzheimer’s disease treatment Go to article: Covid-19 vaccine inequity: the debate over patent waivers intensifies Go to article: Covid-19 vaccines show efficacy in adolescents Go to article: International pharmacovigilance for biotechs: forming a strategy Go to article: Nipro Go to article: HOF Sonderanlagenbau Go to article: Myonex Go to article: In Depth Go to article: Malaria vaccines through the ages Go to article: Are competition authorities tightening the rules on pharma M&A? Go to article: The fishy business of shark squalene Go to article: Without a trace: can pharma reduce scarring?Go to article: Blood plasma production: OK for the UK?Go to article: When the drugs don’t work: can pharma keep up with mental health?Go to article: The Solubility Company - Company Insight Go to article: The Solubility company Go to article: Owen Mumford Company Insight Go to article: Owen Mumford Go to article: In Data Go to article: Deals analysis Go to article: The pharma industry key list Go to article: Global markets and indices Go to article: Macro-economic indicators Go to article: Macro-economic indicators (page 2)Go to article: Events Go to article: Next issue